Trial Profile
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Acronyms ASPIRE
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 06 Nov 2019 Results assessing the long-term durability of clinical benefit, overall survival (OS) and progression-free survival (PFS) for Part 2 patients within Part 2 and Part 3, and safety and tolerability of eltrombopag monotherapy in patients with advanced MDS or AML, were released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 May 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology